Pearlsinmires Headquarters & Office Locations

Pearlsinmires (Private) is headquartered in Seoul, Seoul, South Korea. Founded in 2023, the company operates across 1 countries with approximately 5 employees worldwide.

Where is Pearlsinmires's main office?

Pearlsinmires's main headquarters office is located at 150 Yeongdeungpo-Ro, Seoul, Seoul 07292. This serves as the company's primary corporate address and is home to its executive leadership team.

Pearlsinmires regional offices

Beyond its headquarters in Seoul, Pearlsinmires maintains 1 offices across 1 countries. Regional offices span 1 countries.

Pearlsinmires contact information

The main switchboard for Pearlsinmires headquarters can be reached at —. For investor relations, visit en.pearlsinmires.com/investor-relations.

What does Pearlsinmires do?

[Company Overview] The company is a biotech startup pioneering a paradigm shift in oncology. By moving away from traditional target “inhibition,” the company utilizes a First‑in‑Class “substrate stabilization” mechanism to provide a definitive therapeutic solution for patients with intractable, drug‑resistant cancers who have exhausted existing treatment options. [Core Item: Pearl‑101] 1. Target Indication: The company’s lead asset, Pearl‑101, is being developed for double‑class resistant BRCA‑mutated breast cancer, specifically tumors resistant to both platinum‑based chemotherapy and PARP inhibitors. 2. Mechanism of Action: Pearl‑101 directly binds to and stabilizes Poly(ADP‑ribose) (PAR) polymers. This stabilization prevents PAR degradation, resulting in intracellular PAR accumulation and activation of Parthanatos, a unique caspase‑independent cell death pathway. This mechanism is fundamentally distinct from conventional enzyme‑inhibiting targeted therapies. 3. Key Advantages: - Universal Key for Resistance: Because PAR is a chemical polymer rather than a protein, it is not affected by genetic mutations such as BRCA reversion mutations that commonly drive drug resistance. - High Selectivity & Low Toxicity: Derived from an endogenous peptide, Pearl‑101 selectively targets PAR, which is highly overexpressed only in resistant cancer cells, thereby minimizing toxicity to normal tissues. [Development Status] 1. Pre‑clinical Excellence: The company has identified a high‑affinity lead compound and demonstrated strong in vivo efficacy, achieving over 90% tumor growth inhibition in resistant animal models. 2. Robust Global IP: The company has secured a comprehensive global patent portfolio, with registrations completed in Korea, Europe (38 countries), Japan, Canada, Australia, and India. Patent applications are currently pending in the United States and China. 3. Next Milestones: The company is focused on completing GLP toxicity studies and GMP manufacturing (CMC) to finalize the IND package. The goal is to submit an IND and initiate Phase 1 clinical trials by 2028. [Business Potential & Strategy] 1. Blue Ocean Market: The “Post‑PARPi” resistance market represents a significant unmet medical need with no established standard‑of‑care. This market is projected to reach approximately 8 trillion KRW by 2035. 2. Platform Scalability: Beyond its potential as a standalone therapy for various BRCAness solid tumors (including ovarian and pancreatic cancers), Pearl‑101 also offers strong potential as a novel, low‑toxicity payload for next‑generation antibody‑drug conjugates (ADCs), addressing toxicity limitations associated with current toxin‑based payloads. 3. Business Model: The company’s primary strategy is an early Licensing‑Out model. The company aims to partner with global pharmaceutical companies and ADC developers at the pre‑clinical or Phase 1 stage to generate upfront payments, milestone revenues, and royalties.